

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 11/1/02

Signature: *Anna P. Lucey*

(Anna P. Lucey)



Docket No.: BIIJ-P02-063800/2900

(PATENT)

1646
RECEIVED
NOV 05 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Pepinsky et al.

Application No.: 09/579,680

Group Art Unit: 1646

Filed: May 26, 2000

Examiner: O'Hara, E.

For: **HYDROPHOBICALLY-MODIFIED
PROTEIN COMPOSITIONS AND
METHODS**

#18
MgJ
11/7/02

CORRECTED INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

In response to the Office Action of April 22, 2002 the attention of the Patent and Trademark Office is hereby directed to the references on the attached Form PTO/SB/08. In accordance with 37 CFR 1.98(a)(2) and the aforementioned Office Action, complete copies of references AA-AQ are attached. It is respectfully requested that the information now be expressly considered during the prosecution of this application.

Dated:

Respectfully submitted,

By *David P. Halstead*

David P. Halstead, Ph.D.

Registration No.: 44,735

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys for Applicant

PTO/SB/08		Docket Number (Optional) BIIJ-P02-067		Application Number 09/579,680	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Pepinsky, et al.		Group Art Unit 1646	
		Filing Date 26-May-2000			
<div style="text-align: center;"> U.S. PATENT DOCUMENTS </div>					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE IF APPROPRIATE
AA	5,824,315	10/1998	Nag et al		
AB	5,567,317	10/1996	Kauver		
AC	5,374,548	12/20/94	Caras		
AD	5,399,347	03/21/95	Trentham et al.		
AE	5,130,297	07/14/92	Sharma et al.		
<div style="text-align: center;"> FOREIGN PATENT DOCUMENTS </div>					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS Translation YES NO
AF	WO 99/28343	06/10/99	PCT		
AG	WO 98/30576	07/16/98	PCT		
AH	WO 97/40852	11/06/97	PCT		
AI	WO 96/16668	06/06/96	PCT		
<div style="text-align: center;"> OTHER DOCUMENTS </div>					
(Including Author, Title, Date, Pertinent Pages Etc.)					
AJ	Arimilli, S. et al. Antigen-Specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes. <i>Immunology and Cell Biology</i> 74, 96-104 (1996)				
AK	Busconi L. & Denker, B. M. Analysis of the N-terminal binding domain of G α . <i>Biochem. J.</i> 328, 23-31 (1997).				
AL	Clark, B. R. et al. Antigen-specific Deletion Cloned T Cells Using Peptide-Toxin Conjugate Complexed with Purified Class II Major Histocompatibility Complex Antigen. <i>J. Biol. Chem.</i> 269, 94-99 (1994).				
AM	Everett, K. D. E. et al. Characterization of Lipoprotein EnvA in Chlamydia psittaci 6BC. <i>J. Bacteriology</i> Vol. 176, 6082-6087 (Oct. 1994).				
AN	Karin, N. et al. Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon γ and Tumor Necrosis Factor α Production. <i>J. Exp. Med.</i> 180, 2227-2237 (1994).				
AO	Kleuss C. & Gilman A. G.. Gs α contains an unidentified covalent modification that increases its affinity for adenylyl cyclase. <i>PNAS</i> 94, 6116-6120 (June 1997).				
AP	Moll, T. S. & Thompson, T. E. Semisynthetic Proteins: Model Systems for the Study of the Insertion of Hydrophobic Peptides into Preformed Lipid Bilayers. <i>Biochemistry</i> 33, 15469-15482 (1994).				
AQ	Skolnick, J. & Fetrow, J. S. From genes to protein structure and function: novel applications of computational approaches in the genomic era. <i>Trends in Biotechnology</i> 18, 34-39 (Jan. 2000).				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					